Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation

Journal of Heart and Lung Transplantation

Volumn 24, Issue 1, 2005, Pages 63-66

  Mahle, William T ^a   Vincent, Robert N ^a   Berg, Alexandria M ^a   Kanter, Kirk R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; PRAVASTATIN;

ADOLESCENT; ADULT; ANGIOCARDIOGRAPHY; AUTOPSY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEART TRANSPLANTATION; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT; REVIEW; TREATMENT OUTCOME;

EID: 11844286845     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2003.10.013     Document Type: Article

References (15)

1. Fraund S., Pethig K., Franke U., et al. Ten year survival after heart transplantation palliative procedure or successful longterm treatment? Heart. 82:1999;47-51
2. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627
3. Wenke K., Meiser B., Thiery J., et al. Simvastastin reduces graft vessel disease and mortality after heart transplantation a four-year randomized trial. Circulation. 96:1997;1398-1402
4. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 108:2003;426-431
5. Katznelson S. Immunosuppressive and antiproliferative effects of HMG-CoA reductase inhibitors. Transplant Proc. 31:(3B Suppl):1991;22S-24S
6. Pahl E., Naftel D.C., Kuhn M.A., Shaddy R.E., Morrow R., Kirklin J.J. The incidence of and impact of transplant coronary artery disease in pediatric recipients a 9 year multi-institutional study. Circulation. 10:2002;II-396. (abstr)
7. Mulla N.F., Johnston J.K., Vander Dussen L., et al. Late rejection is a predictor of transplant coronary artery disease in children. J Am Coll Cardiol. 37:2001;243-250
8. Addonizio L.J., Hsu D.T., Douglas J.F., et al. Decreasing incidence of coronary artery disease in pediatric heart transplant recipients using increased immunosuppression. Circulation. 88:(5 Pt 2):1993;II224-II229
9. Hirsch R., Balzer D.T., Dent C.L., Huddleston C.B., Mendeloff E.N., Canter C.E. Outcome after diagnosis of moderate-severe transplant coronary artery disease (TCAD) in pediatric heart transplant recipients. J Heart Lung Transplant. 20:2001;261-262
10. Crowley J., Hu M. Covariance analysis of heart transplant survival data. J Am Stat Assoc. 72:1977;27-36
11. Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 200;20:611-8.
12. Chin C., Gamberg P., Miller J., Luikart H., Bernstein D. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant. 21:2002;1213-1217
13. See V.Y. Jr, DeNofrio D., Goldberg L., et al. Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. Am J Cardiol. 92:2003;11-15
14. Sadeghi M.M., Tiglio A., Sadigh K., et al. Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation. 71:2001;1262-1268
15. Magnani G., Carinci V., Magelli C., Potena L., Reggiani L.B., Branzi A. Role of statins in the management of dyslipidemia after cardiac transplant randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. J Heart Lung Transplant. 19:2000;710-715